RBD 4059
Alternative Names: RBD-4059Latest Information Update: 28 Oct 2024
Price :
$50 *
At a glance
- Originator Suzhou Ribo Life Science
- Class Amino sugars; Antithrombotics; Drug conjugates; Small interfering RNA; Vascular disorder therapies
- Mechanism of Action Factor XI expression inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Coronary artery disease
- Phase I Thromboembolism
Most Recent Events
- 30 Aug 2024 Pharmacokinetics, pharmacodynamics and adverse event data from a phase I trial in Thromboembolism presented at the Annual Congress of the European Society of Cardiology (ESC-2024)
- 28 Aug 2024 Phase-II clinical trials in Coronary artery disease in Sweden (SC) (NCT06717074)
- 25 Aug 2023 Pharmacodynamics and adverse events data from a preclinical trial in thromboembolism presented at the ESC Congress 2023 - Annual Congress of the European Society of Cardiology (ESC-Card-2023)